TS
ELEV

Thomas Steyer’s Elevation Oncology ELEV Stock Holding History

Thomas Steyer’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,527,482
Closed -$1.98M – 150
2024
Q4 		$1.98M Hold
3,527,482
– – 0.01% 96
2024
Q3 		$2.12M Sell
3,527,482
-70,936
-2% -$105K 0.01% 104
2024
Q2 		$9.72M Sell
3,598,418
-288,245
-7% -$1.09M 0.04% 83
2024
Q1 		$19.9M Buy
+3,886,663
New +$12.6M 0.08% 75

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Thomas Steyer's ELEV Position: Q1 2025 in Review

Thomas Steyer sold out of Elevation Oncology (ELEV) in Q1 2025, closing a stake of 3,527,482 shares — an estimated $1.98M sold.

Thomas Steyer first reported a position in ELEV in Q1 2024 and held it in 4 quarters. The position peaked at $19.9M in Q1 2024. 72 funds tracked by Wall St. Rank hold ELEV as of Q1 2025.

  • Thomas Steyer reported no remaining Elevation Oncology position as of Q1 2025 after selling out during the quarter.
  • Thomas Steyer sold 3,527,482 Elevation Oncology shares in Q1 2025, an estimated $1.98M.
  • Thomas Steyer first reported a position in Elevation Oncology in Q1 2024 and held it in 4 quarters.
  • Thomas Steyer's Elevation Oncology position peaked at $19.9M in Q1 2024.
  • 72 funds tracked by Wall St. Rank held Elevation Oncology as of Q1 2025.

Based on Farallon Capital Management's 13F filing for Q1 2025, filed 15 May 2025.